Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05752604

Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer

DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Thyroid Cancer Endocrine Gland Neoplasms Endocrine System Diseases Head and Neck Neoplasms Neoplasms Neoplasms by Site Thyroid Diseases Thyroid Neoplasms

Sex eligibility

All sexes

Study type

Observational

Primary location

Istituto Auxologico Italiano, IRCCS

Milan, 20149, Italy

Location status: Recruiting

Location contact

Laura Fugazzola, MD

CONTACT

[email protected]

+3902619112727

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • thyroid cancer diagnosis

Exclusion criteria

  • patients unable to sign informed consent

Treatment and study plan

Primary outcomes

  1. Dynamic risk stratification

    Time frame: one year from the primary treatment

    impact of the different variables on the DRS

  2. Dynamic risk stratification

    Time frame: five years from the primary treatment

    impact of the different variables on the DRS

  3. Dynamic risk stratification

    Time frame: ten years from the primary treatment

    impact of the different variables on the DRS

  4. Progression-free survival

    Time frame: one year from the primary treatment

    impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer

  5. Progression-free survival

    Time frame: five years from the primary treatment

    impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer

  6. Progression-free survival

    Time frame: ten years from the primary treatment

    impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer

  7. Overall survival

    Time frame: one year from the primary treatment

    impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer

  8. Overall survival

    Time frame: five years from the primary treatment

    impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer

  9. Overall survival

    Time frame: ten years from the primary treatment

    impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer

Study contacts

Contact information is provided by the study sponsor or research team.

Laura Fugazzola, MD

CONTACT

[email protected]

+390261911 ext. 2727

Sponsors and collaborators

Lead sponsor

Istituto Auxologico Italiano

Other

Registry information

Official study title

Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer

Acronym: THY-CANC

Important dates

Study start
2022
Primary completion
2032
Study completion
2042
First posted
Mar 2, 2023
Registry last updated
Aug 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.